Concentration - Effect relationship of cisatracurium at three different dose levels in the anesthetized patient

Anesthesiology

Volumn 95, Issue 2, 2001, Pages 314-323

  Bergeron, Luc ^a   Bevan, David R ^b   Berrill, Andrew ^b   Kahwaji, Raymond ^b   Varin, France ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CISATRACURIUM; FENTANYL; LAUDANOSINE; NITROUS OXIDE; OXYGEN; PROPOFOL;

ADULT; AGED; ANESTHESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034904161     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200108000-00010     Document Type: Article

References (32)

1. Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure
2. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit
3. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation
4. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia
5. Importance of the organ-independent elimination of cisatracurium
6. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients
7. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia
8. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients
9. Dose proportionality of cisatracurium
10. Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium
11. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients
12. 1-isomer of atracurium, in human and rat plasma
13. Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opiod anesthesia
14. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia
15. Pharmacologie des myorelaxants et leurs antagonistes, Anesthésie
16. High performance liquid chromatography assay for cisatracurium and its metabolites in human urine
17. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations
18. General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment
19. Elimination of atracurium in humans: Contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination
20. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine
21. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models
22. Assuming peripheral elimination: Its impact on the estimation of pharmacokinetic parameters of muscle relaxants
23. Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal incubation
24. Comparison of speed of action of fazanidium, pancuronium, tubocurarine and suxamethonium
25. Molecular weight of cation as a determinant of speed of onset of neuromuscular blockade
26. Speed of action of various muscle relaxants at the neuromuscular junction binding vs. buffering hypothesis
27. Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters
28. Pharmacokinetics and pharmacodynamics of a second dose of atracurium in anaesthetised patients
29. Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration
30. Comparison of twitch depression of the adductor pollicis and the respiratory muscles: Pharmacodynamic modeling without plasma concentrations
31. Pharmacodynamic modeling of vecuronium-induced twitch depression: Rapid plasma-effect site equilibration explains faster onset at resistant laryngeal muscles than at the adductor pollicis